<DOC>
	<DOCNO>NCT01112358</DOCNO>
	<brief_summary>This prospective , randomise , comparative parallel control , Phase 2 exploratory trial ass efficacy safety mid follicular Luveris 60 woman risk poor response undergo COS prior ICSI Gonal-f Cetrotide .</brief_summary>
	<brief_title>An Exploratory Trial Assess Efficacy Safety Luveris Women Risk Poor Response Undergoing Controlled Ovarian Stimulation ( COS ) Prior Intracytoplasmic Sperm Injection ( ICSI ) With Gonal-f Cetrotide</brief_title>
	<detailed_description>Large protocol dedicate overcome problem poor ovarian response encourage result obtain . This proposal complement COS follitropin alfa add lutropin alfa time gonadotropin release hormone ( GnRH ) antagonist administration prevent endogenous luteinising hormone ( LH ) surge . The reason : - Recombinant-follicle stimulate hormone ( r-FSH ) promote follicular growth aromatase activation stimulate estradiol ( E2 ) synthesis . - Recombinant-human LH ( r-hLH ) besides act theca cell provide androgens convert E2 , finalize maturation granulosa cell develop follicle , time , produce atresia less developed follicle lack mature granulosa cell . - The use GnRH antagonist strongly suppress serum LH level thus exogenous administration lutropin alfa . OBJECTIVES - To assess efficacy simultaneous addition GnRH antagonist r-hLH versus addition r-hLH , subject risk poor response age &lt; 38 year undergoing COS r-hFSH prior ICSI , term oocyte number quality well follicular development , oocyte fertilisation , embryo quality pregnancy rate - To assess safety use r-hLH combination r-hFSH protocol COS GnRH antagonist , include incidence ovarian hyperstimulation syndrome ( OHSS ) adverse event ( AEs ) well local tolerance . The study organise outpatient basis . All subject underwent COS accord centre´s standard protocol ( Luveris ) GnRH antagonist go use . The COS start day 2-3 cycle initial dose follitropin alfa range 225 450 IU/day depend subject ' baseline profile . Then daily dose adjust accord ovarian response . When detected follicle ≥ 14 mm serum E2 level &gt; 200 pg/ml , 0.25 mg/day Cetrotide 150 IU/day Luveris initiate . Randomisation Luveris supplementation take place time fourth day COS ( S4 ) first dose Cetrotide , administer morning . Once COS complete , follitropin alfa , lutropin alfa , Cetrorelix stop recombinant-human choriogonadotropin ( r-hCG ) administer within follow 24 hour . Standard criteria r-hCG administration presence least one follicle ≥18 mm two addition follicle &gt; 16 mm together appropriate E2 level follicular number size .</detailed_description>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Premenopausal female subject , age &lt; 38 year , wish conceive include ICSIembryo transfer ( ET ) protocol GnRH antagonist Subjects risk poor response least one follow criterion : Previous poor response ≤3 fol ≥14 mm , ≤2 MII , E2 ≤600 pg/l hCG Cancellation previous cycle Early follicular phase serum FSH ≥ 8.5 IU/l Subjects normal baseline LH E2 level normal gynaecological imaging Subjects infertile justify IVF/ET ICSI treatment Subjects able willing adhere protocol informed consent signature Subjects clinically significant disease include know human immunodeficiency virus ( HIV ) , hepatitisB virus ( HBV ) /hepatitisC virus ( HCV ) positivity Subjects 3 previous assist reproductive technique ( ART ) cycle Subjects polycystic ovary , ovarian enlargement cyst unknown aetiology , unexplained gynaecological bleeding Subjects contraindication pregnant , active substance abuse Subjects simultaneously participate another clinical drug trial .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Lutropin alfa</keyword>
	<keyword>Fertilization vitro</keyword>
	<keyword>Intracytoplasmic sperm injection</keyword>
	<keyword>Reproductive technique , assist</keyword>
</DOC>